Compare ICUI & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICUI | ADMA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 1995 | 2012 |
| Metric | ICUI | ADMA |
|---|---|---|
| Price | $125.30 | $9.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $182.25 | $32.00 |
| AVG Volume (30 Days) | 248.8K | ★ 9.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.62 | N/A |
| EPS | 0.03 | ★ 0.60 |
| Revenue | ★ $2,231,262,000.00 | $42,219,783.00 |
| Revenue This Year | N/A | $27.46 |
| Revenue Next Year | $4.46 | $22.11 |
| P/E Ratio | $4,130.50 | ★ $16.36 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $107.02 | $7.21 |
| 52 Week High | $160.29 | $25.67 |
| Indicator | ICUI | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 33.29 |
| Support Level | $122.17 | $7.21 |
| Resistance Level | $135.68 | $16.44 |
| Average True Range (ATR) | 4.24 | 1.02 |
| MACD | 0.38 | -0.00 |
| Stochastic Oscillator | 42.73 | 34.19 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.